These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36739901)

  • 21. Biological therapies (immunomodulatory drugs), worsening of psoriasis and rebound effect: new evidence of similitude.
    Teixeira MZ
    Homeopathy; 2016 Nov; 105(4):344-355. PubMed ID: 27914574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of psoriasis.
    O'Rielly DD; Rahman P
    Pharmacogenomics; 2011 Jan; 12(1):87-101. PubMed ID: 21174624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The unsuitability of using corticosteroid preparations in the treatment of psoriasis in children].
    Grishko TN
    Vestn Dermatol Venerol; 1989; (9):69-71. PubMed ID: 2532822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients.
    Ciolfi C; Balestri R; Bardazzi F; Burlando M; Chersi K; Costanzo A; Dapavo P; Gisondi P; Malagoli P; Pizzolato M; Rech G; Russo FP; Battistella S; Piaserico S
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):e1203-e1207. PubMed ID: 37170951
    [No Abstract]   [Full Text] [Related]  

  • 25. Psoriasis induced by infliximab in a patient suffering from Crohn's disease.
    Manni E; Barachini P
    Int J Immunopathol Pharmacol; 2009; 22(3):841-4. PubMed ID: 19822070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticosteroid iatrogenesis in a patient with palmoplantar psoriasis.
    Gómez Vázquez M; Fernández-Redondo V; Toribio J
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):370-1. PubMed ID: 15096160
    [No Abstract]   [Full Text] [Related]  

  • 27. Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression.
    Yip L; Harrison S; Foley P
    Australas J Dermatol; 2008 Nov; 49(4):250-1. PubMed ID: 18855796
    [No Abstract]   [Full Text] [Related]  

  • 28. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
    Salgueiro P; Lago P; Pedroto I
    J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
    [No Abstract]   [Full Text] [Related]  

  • 29. Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of Psoriasis.
    Gregoire ARF; DeRuyter BK; Stratman EJ
    JAMA Dermatol; 2021 Feb; 157(2):198-201. PubMed ID: 33206132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corticosteroid therapy and side effects involving the skin.
    Med J Aust; 1972 May; 2(22):1220. PubMed ID: 4265874
    [No Abstract]   [Full Text] [Related]  

  • 31. Corticosteroid therapy and side effects involving the skin.
    Med J Aust; 1972 Nov; 2(22):1220. PubMed ID: 4266816
    [No Abstract]   [Full Text] [Related]  

  • 32. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rebound pustular psoriasis after brodalumab discontinuation.
    Khemis A; Cavalié M; Montaudié H; Lacour JP; Passeron T
    Br J Dermatol; 2016 Nov; 175(5):1065-1066. PubMed ID: 27037661
    [No Abstract]   [Full Text] [Related]  

  • 34. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
    Teraki Y; Takahashi A; Inoue Y; Takamura S
    Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B.
    Wong GL; Yuen BW; Chan HL; Tse YK; Yip TC; Lam KL; Lui GC; Wong VW
    Liver Int; 2019 Feb; 39(2):271-279. PubMed ID: 30179316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical corticosteroid therapy in psoriasis vulgaris.
    Trozak DJ
    Cutis; 1990 Oct; 46(4):341-50. PubMed ID: 2133985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.
    Kop EN; Körver JE; Van Ruysevelt D; De Jong EM; Van der Valk PG; Van de Kerkhof PC
    J Dermatolog Treat; 2009; 20(1):67-9. PubMed ID: 18651300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy.
    Broge T; Nguyen N; Sacks A; Davis M
    Inflamm Bowel Dis; 2013 Apr; 19(5):E75-7. PubMed ID: 23435403
    [No Abstract]   [Full Text] [Related]  

  • 39. Risankizumab-induced paradoxical pustular psoriasis.
    McFeely O; Pender E; Victory L; Almutlaq H; Storan E
    Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secukinumab-induced paradoxical pustular psoriasis.
    Dogra S; Bishnoi A; Narang T; Handa S
    Clin Exp Dermatol; 2019 Jan; 44(1):72-73. PubMed ID: 30129214
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.